The FDA’s Oncologic Drugs Advisory Committee voted 17-0 to recommend approval for ABP-215, a biosimilar for bevacizumab (Avastin) to treat a range of solid tumors.
Investigators are seeking to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide will improve the survival of patients with newly diagnosed glioblastoma multiforme with EGFR amplification.
Tumor treating fields reduced the risk of death by 37% and overall survival was extended by a median of 5 months for patients with glioblastoma multiforme, in a landmark analysis of the EF-14 trial.
A brain tumor research group at the UW Carbone Cancer Center focuses on biological studies of patient-derived glioblastoma multiforme (GBM) cancer stem cells, combined with analysis of patient-matched serum-cultured GBM and an annotated GBM tissue microarray, to identify clinically relevant biomarkers.
In neuro-oncology, newfound interest has sparked investigations into metabolic pathways in tumors with the hope of identifying novel therapeutic targets.
The addition of onartuzumab to bevacizumab did not provide any increased clinical benefit in the treatment of patients with recurrent glioblastoma multiforme.
The concept of using immunotherapies to treat patients with glioblastoma multiforme is gaining ground among researchers who are interested not only in evaluating checkpoint blockade agents that have proved effective in other tumor types but also in exploring novel targets.
Researchers are hoping that a proposed phase II study exploring use of the Optune system in patients with recurrent grade III malignant glioma will expand the indications for the tumor treating fields (TTFields) device beyond its current FDA-approved use in recurrent grade IV glioblastoma.
Treatment with nivolumab and radiotherapy with or without concurrent temozolomide was well tolerated and showed promising signs of efficacy for patients with newly-diagnosed glioblastoma multiforme.